Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

Share Price is delayed by 15 minutes
Get Live Data
13.50    0.00 (0.00%)
Bid:
13.25
Ask:
13.75
Spread: 0.50 (3.774%)
Market Cap: £65.58m
CREO Live PriceLast checked at - London Stock Exchange

Intraday Creo Medical Share Chart

City Centre Development

17 Jun 2010 07:00

RNS Number : 7721N
China Real Estate Opportunities PLC
17 June 2010
 



 

CHINA REAL ESTATE OPPORTUNITIES PLC

RECEIPT OF LETTERS FROM VENDORS OF CITY CENTER

 

China Real Estate Opportunities plc ("CREO" or the "Company"), is an AIM-listed company established to acquire investment and development properties in China.

 

On 24 May 2010 and 10 June 2010, CREO and CREO (Shanghai City Centre) Limited (which is a wholly-owned subsidiary of CREO) ("CSCCL") received letters (the "Letters") from the vendors of the City Center property (the "Vendors") requesting certain information, and alleging that certain conditions under the Share Purchase Agreement (as defined below and which was entered into in June 2007) may have occurred or may be likely to occur. If substantiated, the allegation may potentially result in a future payment by CREO of an amount of up to approximately GBP14 million to the Vendors (as defined below).

 

CSCCL and CREO have obtained advice and opinions from both Hong Kong and Peoples Republic of China counsel indicating that the request for information has no basis and any alleged claim for payment as set forth in the Letters have no merit. Accordingly, CSCCL and CREO intend to defend their position vigorously. CSCCL and CREO are of the view that the Letters have been sent at an opportunistic time in light of the impending listing by introduction of Treasury China Trust on Singapore Exchange Securities Trading Limited (the "SGX-ST").

 

CREO will make further announcements as and when there are material developments in the above matters.

 

The City Center Share Purchase Agreement

On 1 June 2007, CSCCL and CREO entered into a share purchase agreement in respect of the acquisition by CSCCL of Brightime Limited and State Properties Limited (the "Share Purchase Agreement") from the Vendors. Brightime Limited and State Properties Limited, through their wholly owned subsidiary Shanghai Hua Tian Property Development Co., Ltd. ("Hua Tian"), own the City Center property in Shanghai.

 

Contact:

 

CREO

Ray Horney, Chairman

Tel: 07797 314 1596

 

Sarah Moriarty, Investor Relations

Tel: +353 1 6189455

 

Matrix Corporate CapitalPaul Fincham Tel +44 (0)20 3206 7000

 

Davy

Des Carville

Tel: +353 1 679 6363

 

Citigate Dewe Rogerson

Tom Baldock

Tel: + 44 (0) 20 7638 9571

 

Murray Consultants

Ed Micheau

Tel: + 3531 498 0300

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUBOVRRNANARR
Date   Source Headline
9th Dec 20207:00 amRNSFirst clinical use of new Creo GI product
24th Nov 20201:36 pmRNSExercise of Options
3rd Nov 20207:00 amRNSAcquisition of Boucart Medical SRL
2nd Nov 20207:00 amRNSUS FDA clearance for MicroBlate™ Fine device
23rd Sep 20207:00 amRNSHalf-year Report
26th Aug 20204:09 pmRNSHolding(s) in Company
11th Aug 20207:00 amRNSExercise of Options
3rd Aug 20207:00 amRNSVideo abstract published endorsing Speedboat
24th Jul 202011:00 amRNSDirector/PDMR Shareholding
24th Jul 20207:00 amRNSAcquisition of Albyn Medical S.L.
13th Jul 202010:37 amRNSSecretary of State for Wales site visit
13th Jul 202010:08 amRNSSecretary of State for Wales site visit
6th Jul 20207:00 amRNSDirectorate Change
2nd Jul 20207:00 amRNSDevelopment loan for plasma sterilising product
24th Jun 202010:30 amRNSResult of AGM
15th Jun 20207:00 amRNSCE mark for five new devices
8th Jun 20207:00 amRNSIET Prize nomination
3rd Jun 20207:00 amRNSPositive NHS health economics data
27th May 20207:00 amRNSPosting of Annual Report & Notice of AGM
20th May 20207:00 amRNSCommercialisation Agreement
7th May 20207:00 amRNSFinal Results
23rd Mar 20207:00 amRNSFDA Clearance for HS1 Haemostasis Device
20th Mar 20207:00 amRNSTrading update – COVID-19 impact
4th Mar 20205:00 pmRNSExercise of Options
24th Feb 20203:49 pmRNSHolding(s) in Company
19th Feb 20207:00 amRNSLTIP Awards and Issue of Equity
11th Feb 20207:00 amRNSVideo abstracts re. Speedboat procedures in India
7th Feb 202011:50 amRNSExercise of Options
6th Feb 20207:00 amRNSGrowth & Innovation Forum 2020
3rd Feb 20207:00 amRNSAppointment of NED
30th Jan 20207:00 amRNSTrading update
30th Dec 20193:17 pmRNSHolding(s) in Company
27th Dec 20195:00 pmRNSHolding(s) in Company
24th Dec 20198:01 amRNSDirector/PDMR Shareholding
23rd Dec 201911:15 amRNSResult of General Meeting and Total Voting Rights
23rd Dec 20197:00 amRNSResult of Open Offer
4th Dec 20197:00 amRNSRe. Placing, Open Offer, and Posting of Circular
2nd Dec 20197:00 amRNSFundraising and Launch of Accelerated Book Build
20th Nov 20197:00 amRNSFirst in-human cases in India
22nd Oct 20197:00 amRNSCommercial Launch of Speedboat at UEG Week
17th Oct 20197:00 amRNSUK Endoscopy Training Course
30th Sep 20197:00 amRNSHalf-year Report
26th Sep 20197:00 amRNSFramework Distribution Agreement for India
23rd Sep 20192:16 pmRNSNotice of Results
10th Sep 20197:00 amRNSUS Clinical Education Programme enters Phase II
7th Aug 20191:57 pmRNSDirector/PDMR Shareholding
5th Jul 20197:00 amRNSInstitute of Physics Award
25th Jun 20197:00 amRNSFirst commercial orders for Speedboat
6th Jun 20191:23 pmRNSResult of AGM
13th May 201910:50 amRNSAnnual Reports & Accounts & Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.